Nucleotide analogues as inhibitors of SARS‐CoV Polymerase

Nucleotide analogues as inhibitors of SARS‐CoV Polymerase

Abstract SARS‐CoV‐2, a member of the coronavirus family, has caused a global public health emergency. Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA‐approved hepatitis C drug...

Full description

Bibliographic Details
Main Authors: Jingyue Ju, Xiaoxu Li, Shiv Kumar, Steffen Jockusch, Minchen Chien, Chuanjuan Tao, Irina Morozova, Sergey Kalachikov, Robert N. Kirchdoerfer, James J. Russo
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Pharmacology Research & Perspectives
Subjects:
COVID‐19
SARS‐CoV
SARS‐CoV‐2
RNA‐dependent RNA polymerase
nucleotide analogue
Online Access:https://doi.org/10.1002/prp2.674

Internet

https://doi.org/10.1002/prp2.674

Similar Items